Latest Immunotherapy Approaches in Multiple Myeloma

Video

This video highlights novel approaches using immunotherapies and vaccines for advancing treatment in multiple myeloma.

In this video, Ivan Borrello, MD, of Johns Hopkins University in Baltimore, Maryland, discusses novel approaches with immunotherapies and vaccines for advancing treatment in multiple myeloma.

Borrello gave a presentation on this topic at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Related Content
Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera

Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera

Ariana Pelosci
August 28th 2025
Article
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 28th 2025
Podcast
Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations

Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations

American Society for Transplantation and Cellular Therapy
August 28th 2025
Article
An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
August 28th 2025
Podcast
Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenstrom macroglobulinemia.

Generic Ibrutinib Tablets Earn Tentative FDA Approval in Blood Cancers

Russ Conroy
August 28th 2025
Article
Many patients reported social/financial vulnerabilities that possibly precluded them from transplant access outside of the phase 2 clinical trial.

Cyclophosphamide-Based GVHD Prophylaxis May Improve Survival in HSCT

Roman Fabbricatore
August 28th 2025
Article